Drugs / Mafosfamide
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00031928 | Jan 2002 → ? | central nervous system neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00062881 | Jun 1990 → Sep 2005 | malignant tumor of meninges | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00001251 | Nov 1989 → Nov 2003 | leukemia, lymphoma, tumor of meninges | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00042367 | Apr 2000 → Dec 2005 | brain cancer | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mafosfamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001251 ↗ |
| Known as | Mafosfamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL59990 ↗ |
| Modality | Small molecule | — CHEMBL59990 ↗ |
| Route | Intrathecal | “Mafosfamide will be administered intrathecally” NCT00001251 ↗ |